Abstract Identifying risk factors for lymphedema in patients treated for breast cancer has become increasingly important, given the current lack of standardization surrounding diagnosis and treatment. Reports on the association of body mass index (BMI) and weight change with lymphedema risk are conflicting. We sought to examine the impact of pre-operative BMI and post-treatment weight change on the incidence of lymphedema. From 2005 to 2011, 787 newly diagnosed breast cancer patients underwent prospective arm volume measurements with a Perometer pre-and post-operatively. BMI was calculated from same-day weight and height measurements. Lymphedema was defined as a relative volume change (RVC) of C10 %. Univariate and multivariate Cox proportional hazards models were used to evaluate the association between lymphedema risk and pre-operative BMI, weight change, and other demographic and treatment factors. By multivariate analysis, a pre-operative BMI C30 was significantly associated with an increased risk of lymphedema compared to a pre-operative BMI \25 and 25-\30 (p = 0.001 and p = 0.012, respectively). Patients with a pre-operative BMI 25-\30 were not at an increased risk of lymphedema compared to patients with a pre-operative BMI \25 (p = 0.409). Furthermore, a cumulative absolute weight fluctuation of 10 pounds gained/lost per month postoperatively significantly increased risk of lymphedema (HR: 1.97, p = \ 0.0001). In conclusion, pre-operative BMI of C30 is an independent risk factor for lymphedema, whereas a BMI of 25-\30 is not. Large post-operative weight fluctuations also increase risk of lymphedema. Patients with a pre-operative BMI C30 and those who experience large weight fluctuations during and after treatment for breast cancer should be considered at higherrisk for lymphedema. Close monitoring or early intervention to ensure optimal treatment of the condition may be appropriate for these patients.
Introduction
As survival from breast cancer increases, management of long-term treatment complications, especially those that impact quality of life, has gained greater significance. Lymphedema is a chronic condition characterized by the accumulation of protein-rich fluid in the interstitial tissues of the arm, breast, or chest wall. The swelling, that is characteristic of lymphedema, has the potential to compromise a patient's physical and psychological well-being [1] [2] [3] [4] . Breast cancer survivors who have undergone surgical lymph node removal and/or radiation therapy may be at a lifelong risk of developing lymphedema [5] . It is estimated that approximately one in five breast cancer patients will develop lymphedema [6] . Therefore, lymphedema remains an important complication of breast cancer treatment.
The most commonly cited risk factor for lymphedema following breast cancer treatment is axillary lymph node dissection (ALND) [6] [7] [8] [9] [10] [11] . Other treatment-related risk factors have been suggested, including mastectomy [2, 6, 9, 12] , extent of axillary surgery [6, [13] [14] [15] [16] , number of positive lymph nodes [8, 9, 17, 18] , chemotherapy [8, 10, 11, 14] , and nodal radiation [9, 14, [19] [20] [21] . In addition, elevated body mass index (BMI) has frequently been reported as a risk factor for lymphedema, yet results are conflicting [7, 8, 11, 13, 15, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Some studies suggest that only obesity (BMI C30) is associated with an increased risk of lymphedema, yet others report that being overweight (BMI 25-\30) may also increase lymphedema risk. Reports on the association between post-operative weight change and lymphedema risk are also inconsistent, with weight gain only occasionally identified as a risk factor for lymphedema. Furthermore, most studies investigating the association of BMI and weight gain with lymphedema risk are retrospective, limited by small sample sizes, lack of preoperative assessment, and/or varying methods of defining, measuring, and quantifying lymphedema.
Understanding the impact of BMI and weight change on lymphedema risk is important given that these are potentially modifiable risk factors. We sought to evaluate the impact of pre-operative BMI and post-operative weight change on the risk of lymphedema among patients treated for breast cancer.
Materials and methods

Design and participants
From 2005 to 2011 and with Partners Healthcare Institutional Review Board approval, patients undergoing treatment for primary breast cancer at our institution underwent prospective lymphedema screening via Perometer arm volume measurements. All patients included in this analysis underwent a pre-operative Perometer measurement and subsequent post-operative measurements corresponding with oncology follow-up visits. BMI was calculated from same-day weight and height measurements corresponding with Perometer arm volume measurements, and patient demographic and treatment data were collected via medical record review. Patients who underwent bilateral breast surgery were excluded from the analysis, and measurements occurring after a patient was diagnosed with metastatic disease were also excluded.
Lymphedema
Lymphedema was quantified according to the relative volume change (RVC) equation, which calculates relative change in arm volume compared to the pre-operative assessment and accounts for change in size of the contralateral arm as a control [32] . Briefly, RVC = [(A 2 U 1 )/ (U 2 A 1 ) -1], where A 1 and A 2 are arm volumes on the side treated for breast cancer at pre-operative assessment and post-operative follow-up, and U 1 and U 2 are arm volumes on the contralateral side at the corresponding time points. The RVC equation accounts for change in volume of the contralateral arm, and thereby accounts for factors unrelated to lymphedema which could cause changes in arm size, such as weight gain. The RVC equation has been previously demonstrated to reduce the likelihood of a false positive diagnosis of lymphedema due to fluctuations in arm size related to body size or habitus [33] .
Lymphedema was defined as an RVC C10 % based on consensus within the literature [9, 34] , occurring[3 months post-operative. The time from surgery to initial development of lymphedema (RVC C10 %) was calculated. Patients who never developed lymphedema were considered censored at the time of most recent follow-up visit. The Kaplan-Meier method was used to estimate and plot the cumulative incidence of lymphedema during follow-up.
BMI, weight change, and lymphedema risk Univariate and multivariate Cox proportional hazards models were used to assess the association between lymphedema and pre-operative BMI, categorized as \25 (''normal/underweight''), 25-\30 (''overweight'') and C30 (''obese''), as well as demographic and treatment factors. Time-dependent covariates were used for adjuvant chemotherapy and radiation therapy, such that patients were included in the ''untreated'' category until initiation of a given treatment, and included in the ''treated'' category thereafter.
Several time-dependent variables were constructed to evaluate the association between post-operative change in weight and risk of lymphedema. These included the percent (%) change in weight relative to pre-operative weight, the weight fluctuation relative to the previous measurement, the absolute fluctuation in weight relative to the previous measurement (example below), and the cumulative absolute fluctuation in weight from pre-operative measurement (example below). Each of the four weight change variables were calculated at each follow-up weight measurement and the final three were calculated as rates of change (lbs/month) to account for the variability in time between post-operative measurements. Table 1 provides examples of how these weight change variables were calculated using a fictional patient measured at 1-month intervals from pre-operative. Two-way interactions among significant variables were evaluated by adding interaction terms to the multivariate model. 
Results
Patient characteristics
787 patients met eligibility criteria. Patient demographic and treatment characteristics are listed in Table 2 . The median post-operative follow-up was 27 months (range 6-68), and the median age at diagnosis was 56 (range 27-89). The median pre-operative BMI was 26 kg/m 2 (range 17-50). At the preoperative measurement, 40 % (311/787) of patients had a BMI \25, 33 % (258/787) had a BMI 25-\30 and 28 % (218/787) had a BMI C30. The cumulative incidence of lymphedema was 5 % (95 % CI 3.5-6.9 %) at 2 years postoperative. The cumulative incidence of lymphedema at 2 years post-operative for patients with a pre-operative BMI \25 was 2.6 % (95 % CI 1.2-5.5 %), 25-\30 was 4.4 % (2.3-8.4 %), and C30 was 8.9 % (5.6-14.1 %) ( Fig. 1) .
Analysis of post-operative weight change revealed a median increase in weight from pre-operative of 0.3 % (range -28.5 to 36.6 %), with a median weight change from previous measurement of 0 lbs/month (range -32.6 to 37.5 lbs/month) and a median absolute fluctuation of 0.6 pounds gained or lost per month from previous measurement (range 0-37.5 lbs/ month). The median cumulative absolute weight fluctuation was 3.1 pounds gained or lost per month from pre-operative measurement (range 0-39.9 lbs/month).
BMI, weight change, and risk of developing lymphedema
Univariate results for association of demographic and treatment factors with risk of lymphedema are shown in Table 2 . Patients with a pre-operative BMI C30 had a 4.5-fold increased risk of lymphedema compared to BMI \25 (p = 0.0001), and a threefold increased risk compared to BMI 25-\30 (p = 0.002). Pre-operative BMI 25-\30 was not significantly associated with increased risk of lymphedema as compared to BMI \25 (p = 0.374).
By univariate analysis, absolute weight fluctuation from previous measurement was significantly associated with an increased risk of lymphedema; for each pound gained or lost per month from previous measurement, there was a 1.13-fold increased risk of developing lymphedema (p = 0.007). The cumulative absolute weight fluctuation from pre-operative was also significantly associated with increased risk of lymphedema; each pound gained or lost per month from preoperative incurred a 1.10-fold increased risk of lymphedema (p = \ 0.0001). Percent change in weight from pre-operative was not significantly associated with lymphedema risk (p = 0.508), nor was the weight fluctuation from previous measurement (p = 0.216). Univariate values for other factors are listed in Table 2 . By multivariate analysis, an increased risk of lymphedema was significantly associated with the following factors: pre-operative BMI C30 compared to pre-operative BMI \25 and BMI 25-\30 (HR: 3.58, p = 0.001 and HR: 2.46, p = 0.012, respectively), regional lymph node radiation (RLNR) (HR: 2.67, p = 0.011), and ALND (HR: 4.47, p = 0.0003). Cumulative absolute fluctuation in weight from pre-operative was also significantly associated with an increased risk of lymphedema (HR: 1.07 for every 1 lb/month change in weight, p \ 0.0001) ( Table 3) . This means that a cumulative weight fluctuation of 10 pounds gained/lost per month would result in a 1.97-fold increased risk of lymphedema. Furthermore, a cumulative weight fluctuation of 13.3 pounds gained/lost per month would result in a 2.46-fold increased risk of lymphedema, which is equivalent to the increase in risk associated with preoperative BMI C30 compared to pre-operative BMI 25-\30. A pre-operative BMI 25-\30 was not significantly associated with increased lymphedema risk compared to pre-operative BMI \25 (p = 0.409).
Discussion
Our data suggest that a pre-operative BMI C30 significantly increases the risk of lymphedema, whereas a pre-operative BMI of 25-\30 does not significantly increase risk. We also found that cumulative absolute weight fluctuation from preoperative increases the risk of lymphedema. Specifically, large cumulative absolute fluctuations in weight (as a gain or loss), are associated with increased risk of lymphedema.
Patients with a pre-operative BMI C30 or those who experience significant weight fluctuations (i.e., a combination of both weight loss and weight gain over time, but not each independently) relative to pre-operative should be closely monitored for lymphedema. In this study, a pre-operative BMI C30 was significantly associated with an increased risk of developing lymphedema compared to a pre-operative BMI \25 or 25-\30.
This finding supports the findings of Ridner et al., who investigated the impact of BMI and obesity on the development of lymphedema in 138 patients utilizing Perometer arm volume measurements and symptom assessment preoperatively and up to 30 months post-operatively. They found that a pre-treatment BMI C30 significantly increased the risk of developing lymphedema by 3.6-fold compared to a pre-treatment BMI \30 [23] . Similarly, we found that a pre-operative BMI C30 significantly increased the risk of developing lymphedema by 3.6-fold compared to a preoperative BMI \25 and by 2.5-fold compared to a preoperative BMI of 25-\30. Since weight loss prior to breast cancer treatment is not feasible, we suggest that these highrisk patients be carefully monitored for the development of lymphedema. Arm measurements prior to and after breast cancer treatment may be especially critical in those patients with a pre-operative BMI C30. In addition, education regarding lymphedema risk should begin pre-operatively and continue post-operatively with appropriate instruction concerning potential risk reduction and management strategies.
Many studies that have reported on the association between BMI and lymphedema risk are limited by inaccurate lymphedema assessment techniques and timing (Table 4) . In this way, the use of Perometry and preoperative assessment of lymphedema provide strength to our study. The Perometer is known to ensure accurate and reliable data for quantifying lymphedema as a volume change between arms [35] . Obtaining pre-operative arm volume measurements is also critical to allow for the normal asymmetry, which may exist between arms to be considered when assessing post-operative changes [5, 36] . Although Ahmed et al., Norman et al., and Meeske et al. identified BMI C30 as a risk factor for lymphedema among cohorts of 1,287, 631, and 494 patients, respectively, they measured lymphedema by self-report and they did not incorporate pre-operative lymphedema assessment [8, 11, 13] . Kwan et al. [24] revealed a similar finding among a cohort study of 997 patients, but lymphedema diagnosis was based upon medical record review and BMI data were also collected via self-report. Other studies identifying a significant association between BMI and lymphedema risk have utilized water displacement or circumferential arm measurements to measure lymphedema [7, 15, [25] [26] [27] [28] [29] 31 ], but these methods are subject to greater error and are more time-consuming than Perometry.
It is also important to note that, to our knowledge, this is the largest cohort study (N = 787) investigating the association between BMI and lymphedema risk using a lymphedema diagnosis based on relative arm volume change criterion (i.e., the RVC equation). Relative arm volume change can be used to accurately quantify lymphedema independent of body size. This is in contrast to the use of absolute arm size change, in which specificity depends strongly on patient body size. Recently, Ancukiewicz et al. [33] conducted a study in which the authors evaluated the effect of an absolute change in arm size of 200 ml or 2 cm compared with relative arm volume change as criteria for defining lymphedema. They found that temporal changes in the absolute volume of the unaffected arm were correlated with body size measures such as preoperative arm volume, BMI, and weight, whereas relative arm volume changes were not. Thus, when lymphedema diagnosis is based on absolute criteria, the specificity depends on body size, increasing the chances of a false positive lymphedema diagnosis-crossing at random a threshold of specific size, for example, 2 cm or 200 mlfor larger patients. Conversely, when using relative arm volume change, the magnitude of random variation does not depend on patient body size. Many of the studies listed in Table 4 used absolute criteria (200 ml or 2 cm) to diagnose lymphedema, which may have necessarily correlated with patient BMI. Thus, high BMI could result in spurious associations with lymphedema because of false positives related to the use of absolute arm size changes and the fact that arm size fluctuations unrelated to lymphedema have higher magnitude in such patients. In our series, a pre-operative BMI of 25-\30 was not significantly associated with an increased risk of lymphedema. Previous reports on the association of BMI 25-\30 with lymphedema risk (Table 4 ) are conflicting and confounded by the limitations described above. A few prior studies have reported that a BMI C25 is significantly associated with an increased risk of developing lymphedema. In Swenson et al.'s [26] case-control study of 188 patients, the authors utilized circumferential tape measurement and symptom assessment to assess patients at only one postoperative time point, did not perform pre-operative assessments, and utilized self-reported BMI data. Incorporation of pre-operative arm volume measurements and contralateral arm measurements in lymphedema quantification is essential to account for any normal asymmetry between arms and changes in arm volume which may be caused by factors unrelated to lymphedema, such as weight gain. Likewise, Soran et al.'s case-control study of 156 women suggests that a BMI C25 increases lymphedema risk, yet their study is retrospective in nature and uses a relatively small sample size [28] . Furthermore, Clark et al.'s [29] finding that a BMI C26 increases lymphedema risk is similarly limited by the use of circumferential tape measurements and 25.1 % loss to follow-up resulting in a relatively small sample size of 188 patients. In light of these limitations and lack of evidence from more recent studies supporting BMI C25 as a risk factor for lymphedema, our finding that a pre-operative BMI 25-\30 does not increase lymphedema risk may be significant; however, further research is warranted.
In this study, we found that large post-operative fluctuations in weight (a combination of increases and decreases, and not weight gain or weight loss alone) significantly increased a patient's risk of developing lymphedema. Specifically, a cumulative absolute weight fluctuation of 10 pounds gained/lost per month resulted in a 1.97-fold increased risk of lymphedema. Perhaps more illustrative is the fact that a cumulative absolute weight fluctuation of 13.3 pounds gained/lost per month resulted in a 2.46-fold increased risk of lymphedema, which is equivalent to the increase in risk associated with preoperative BMI C30 compared to pre-operative BMI 25-\30. To our knowledge, this is the first study to report on the association of cumulative absolute weight fluctuation with lymphedema risk. Other studies have reported on weight gain alone as a risk factor for lymphedema. Cormier et al. and Petrek et al. [22, 30] proposed that post-treatment weight gain is a risk factor for lymphedema. Conversely, studies by McLaughlin et al. [7] and Goldberg et al. [15] suggest that weight gain does not predict lymphedema development (Table 4) . Weight gain is a common issue for many women during breast cancer treatment and has been linked to poorer breast cancer prognosis, serious co-morbid conditions such as diabetes and cardiovascular disease, functional decline, and poorer health and overall quality of life [22, [37] [38] [39] [40] [41] [42] . Among these treatment-associated side effects, the potential association between weight gain and increased lymphedema risk provides another reason for the importance of weight management during and after breast cancer treatment as a means to potentially reduce risk.
In addition to weight gain, weight loss alone was not significantly associated with increased lymphedema risk in our study. This finding is consistent with those of the current literature. In fact, the work of Shaw et al. [43] suggests that ''weight loss achieved by dietary advice to reduce energy intake can reduce breast cancer-related lymphedema significantly''. This conclusion was the result of a randomized-controlled 12-week intervention trial in which 21 women were randomized either to receive dietary advice for weight reduction or to receive a booklet on general healthy eating. They found a significant reduction in lymphedema, body weight, and BMI among the weightreduction group at the end of the intervention period. Importantly, lymphedema was measured via circumferential arm measurements with the use of absolute arm volume change, suggesting that weight loss necessarily contributed to a change in arm volume. Our findings suggest that a 10 pound cumulative absolute fluctuation in weight (i.e., a combination of both weight gain and loss) per month increases the risk of developing lymphedema almost twofold. Although the etiology is unclear, we hypothesize that dramatic weight loss may leave the outlying skin elongated and overstretched as the area underneath it had been previously occupied by adipose tissue. This overly extensible soft tissue state may impact lymphatic drainage, as the superficial lymphatic structures may not have regained enough contractility to transport the lymphatic load effectively.
Our study is limited in that we did not include any correlative symptom or quality of life data to assess lymphedema in conjunction with objective Perometer measurements. In addition, lymphedema and BMI assessments were not conducted at the same time points among all patients; rather, patients were evaluated every 3-8 months after surgery depending upon when their next visit to the clinic was. As a result of this non-standard measurement schedule, women who experienced lymphedema symptoms tended to be measured more often, increasing the likelihood for observing an RVC [10 % in these women compared to those who were not symptomatic but had an elevated RVC.
In our series, a pre-operative BMI C30 was associated with an increased risk of developing lymphedema, whereas a pre-operative BMI of 25-\30 was not. Large cumulative absolute weight fluctuations (as a combination of weight gain and weight loss, not each individually) relative to preoperative may also be predictive of increased lymphedema risk (i.e., a cumulative weight fluctuation of 10 pounds gained/lost per month increases the risk of developing lymphedema nearly twofold). Patients with a pre-operative BMI C30 and those who experience significant postoperative weight fluctuations should be closely monitored for lymphedema given their increased risk. Lymphedema monitoring and education should be initiated prior to breast cancer treatment and continue post-operatively with the Table 4 Previous studies reporting on the association of BMI and/or weight gain with lymphedema development vary in sample size, follow-up time, lymphedema assessment method, the use of pre-operative lymphedema assessment, lymphedema incidence, and findings incorporation of appropriate risk reduction and management strategies.
